Pharmacodynamics

Download Report

Transcript Pharmacodynamics

Pharmacodynamics

Collected and Prepared By S.Bohlooli, PhD

LOCUS OF ACTION “RECEPTORS

Bound Free TISSUE RESERVOIRS Free Bound ABSORPTION Free Drug Bound Drug SYSTEMIC CIRCULATION EXCRETION BIOTRANSFORMATION

Molecular pharmacology :

    Molecular pharmacology is concerned with studies of basic mechanisms of drug actions on biological systems.

The idea that drugs act upon specific sites (receptive substance) began with John New Port Langley (1852 1926) of Cambridge.

However the word ‘receptor’ is given by Paul Ehrlich (1854- 19 15).

The receptor concept which forms a key note in the development of molecular pharmacology became firmly established by the quantitative work of Alfred Joseph Clark (1885-1941), a professor of pharmacology at Kings College London.

Receptor (key element)

   In addition to its usefulness for explaining biology, the receptor concept has important practical consequence for The development of drugs Arriving at therapeutic decisions in clinical practice.

Receptors:

 Largely determine the quantitative relations between dose or concentration of drug and pharmacologic effects  Are responsible for selectivity of drug action  Mediate the actions of pharmacologic antagonists

Macromolecular nature of drug receptors

 Regulatory proteins  Enzymes  Transport proteins  Structural proteins

Quantitative aspects of drug-receptor interaction

Drug-Receptor Interactions Obey the Law Of Mass Action

At equilibrium

D

R k

1 

k

2

DR

effect

By law of mass action: [

D

].[

R

].

k

1  [

DR

].

k

2 Therefore:

k

2 

K D k

1  [

D

].[

R

] [

DR

]

K D

 [

D

].[

R

] [

DR

] Total number of receptors: R t = [R] + [DR] [R] = R t – [DR]

K D

 [

D

].(

R t

 [

DR

] [

DR

])  [

D

].

R t

 [

D

[

DR

] ].[

DR

] After rearrangement: [

DR

] 

K

[

D D

].

R t

 [

D

] [

DR

] 

R t K D

[

D

]  [

D

]

When [D] = K D [DR] = 0.5

R T 1.00

0.75

0.50

0.25

0.00

0

K D

5

[

DR

] 

R t K D

[

D

]  [

D

]

10 [D] 15 20

Receptor Binding

K D Concentration of Ligand The dose-response relationship (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill, 1996).

Relation between drug dose & clinical response

Drugs are described based on the magnitude of two properties:

1.

Affinity for the receptor. Affinity is related to potency.

2.

Efficacy once bound to the receptor. Efficacy refers to the maximal effect the drug can elicit.

Agonists and Antagonists

AGONIST

- Has affinity for receptor and efficacy.

ANTAGONIST

- Has affinity but no efficacy.

 Competitive Antagonist  Noncompetitive Antagonist  

Partial Agonist

or Partial Antagonist – Has affinity but

lower

efficacy than full agonist.

Receptor ligand types

Full Agonists (i.e., equal efficacies ) that Differ In Potency :

A B C

Compare the EC50s

Drug Concentration (log scale)

Agonists That Differ in Efficacy

A B C Log Drug Concentration

100 Full and partial agonist occupancy and response relationship Response (full agonist) Occupancy (both) 50 Response (partial Agonist) 0.0

0.01

0.1

Concentration (umol/l) 1.0

10.0

Inverse agonist

Inverse agonist can exist where an appreciable level of activation may exist even when no ligand is present For example: receptors for benzodiazepines , cannabinoids and dopamine Under such condition it may be possible for a

ligand

to reduce the level of activation. such drugs are known as

inverse agonist

Competitive Antagonism Shifts The Agonist D-R Curve (

Potency

)

AG alone AG + ANT

EC 50 EC 50

Drug Concentration (log scale)

Noncompetitive Antagonism Decreases Agonist

Efficacy

AG alone AG + NC ANT AG + higher dose NC ANT Log Drug Concentration

Spare receptor

Receptors are said to be ‘ spare ’ for a given pharmacological response when the maximal response can be elicited by an agonist at a concentration that not result in occupancy of the full complement of available receptors alone antagonist in Agonist with noncompetitive antagonist in presence of spare receptor absence of spare receptor Log Concentration

Antagonist like to bind to receptor in R and R” state without any preference and makes no shifts in net equilibrium L R No effect Agonist like to bind to receptor in R’ state and shifts the equilibrium toward more LR’ and R’ makes effect L Effect LR LR’ Inverse agonist has more affinity to receptor in R state and shifts the Partial agonist has a little more affinity for receptor in R’ equilibrium toward more LR and make negative states than R state and makes partial effect response than resting state.

Possible mechanism for the partial agonist phenomenon.

Desensitization and Tachyphylaxis  Desensitization  Tolerance  Refractoriness  Drug resistance How?

 Changes in receptor  Loss of receptor  Exhaustion of mediators  Increased metabolic degradation  Physiological adaptation  Active extrusion of drug from cells

Drug Antagonism Pharmacologic Chemical Pharmacokinetic Physiologic Propranolol & norepinephrine Dimercaprol & heavy metals Phenobarbital & warfarine Epinephrine & histamine

Signaling mechanism & drug action

Type of receptors

 Ligand gated ion channels  G protein coupled receptors  Ligand-Regulated Transmembrane Enzymes Including Receptor Tyrosine Kinases  Cytokine Receptors  Intracellular receptors

Ligand gated ion channel (iontropic receptors)

  -amino butyric acid (GABA)  Glycine  Aspartate  Glutamate  Acethylcholine  Serotonin

Ligand gated ion channel (iontropic receptors)

ions R Hyper polarization or depolarization Cellular effects

G protein coupled receptors

           Adernocorticotropic hormone Acetylcholine Angiotensin Catecholamines Chrionic gonadotropin Follicle stimulating hormone Glucagon Histamine Luteinizing Hormone Seretonin Vasopressin

Ions

G protein coupled receptors

+ G R Change in excitability

E

+ G Second messengers Ca 2+ release Protein phosphorylation other Cell effects

Kinase linked receptors

 

Ligand -regulated transmembrane enzyme including receptor tyrosine kinases

 Insulin     Epidermal growth factor (EGF) Platelet-derived growth factor (PDGF) Arterial natriuretic factor (ANF) Transforming growth factor  (TGF  )

Cytokine receptors

   Growth hormone Erythropoietin Interferones

Kinase linked receptors

R/E Protein phosphorylation Gene transcription Protein synthesis Cellular effects

Nuclear receptors

Nucleus R Gene transcription Protein synthesis Cellular effects

Well Established Second Messengers  Cyclic Adenosine Monophosphate (cAMP)  Calcium and Phosphoinositides  Cyclic Guanosine Monophosphate (cGMP)

Good Luck